Related Experiment Video
Updated: Sep 11, 2025
08:59
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
10.8K
Exploring the Neurobiological Mechanisms of Cancer Growth
Md Sadique Hussain1, Mudasir Maqbool2, Mohit Agrawal3
1Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehradun, 248007, Uttarakhand, India.
Current Pharmaceutical Design
|August 15, 2025
Summary
The nervous system actively shapes cancer progression. Targeting cancer-neural networks offers new therapeutic strategies for aggressive tumors and improved patient outcomes.
Area of Science:
- Neuroscience
- Oncology
- Cancer Biology
Background:
- Interactions between the nervous system and tumors influence cancer progression, metastasis, and treatment effectiveness.
- Neural components within the tumor microenvironment (TME) play a dynamic role in tumor development.
- Neural signals and structural changes in the TME promote tumorigenesis and cancer cell plasticity.
Purpose of the Study:
- To elucidate the neurobiological mechanisms driving tumor development.
- To highlight the role of neural components in the tumor microenvironment (TME).
- To explore novel therapeutic strategies by understanding cancer-neural interactions.
Main Methods:
- Review of emerging evidence on neurobiological mechanisms in cancer.
- Analysis of neural signals and structural adaptations in the TME.
- Investigation of molecular pathways (e.g., PIK3CA mutations, neurotransmitter signaling) and cellular interactions (e.g., pseudo-tripartite synapses).
Main Results:
- Neural signals stimulate tumorigenesis and cancer cell plasticity.
- Astrocytic glial cells release neurotrophic factors supporting metastasis and survival.
- Cancer cells form pseudo-tripartite synapses with neurons, enhancing proliferation and invasion.
- Cancer-neural networks drive tumor growth and associated symptoms (seizures, pain).
- Tumor metabolic stress activates nociceptive neurons, sustaining progression.
Conclusions:
- Understanding neurobiological interactions opens avenues for novel therapeutic strategies.
- Precision neuro-oncology can target neurotrophic signaling, synaptic pathways, and neuronal differentiation.
- Biomarker research in neuro-tumors aids diagnostics and prognostics.
- Integrating neuroscience into oncology offers a paradigm shift for treating aggressive cancers.
Keywords:
Cancer metastasismetastasisneuronal plasticityneurotrophic factorssynaptic transmissiontumor microenvironmentMore Related Videos
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
02:18Cancer
49.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
49.5K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:21Cancers Originate from Somatic Mutations in a Single Cell
12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:38Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K